Eine Studie mit Beteiligung von Prof. Diener hat die Wirksamkeit des Antiepileptikas in der Prophylaxe der Migräne-Aura untersucht. Dabei wurden die folgenden Ergebnisse erzielt:
- Die durchschnittliche Aura-Häufigkeit reduzierte sich von 1,5 auf 0,4 pro Monat.
- Die durchschnittliche Aura-Dauer reduzierte sich von 27 Minuten auf 8 Minuten.
- 3/4 aller Betroffenen, die eine Verbesserung ihrer Aura feststellten, erlebten auch eine Reduzierung ihrer Migräneattacken und zwar von durchschnittlich 2,1 auf 1,2 pro Monat.
Abstract:
Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura
C Lampl, Z Katsarava, H-C Diener and V Limmroth
This study examined the efficacy of lamotrigine in the prevention of migraine aura. Fifty nine patients suffering from migraine with aura received lamotrigine in a controlled three year prospective open study. Treatment response was defined as a reduction of aura frequency each month by at least 50%. Primary endpoint was reached by three quarters of the patients. Lamotrigine significantly reduced both frequency of migraine aura (mean, 1.5 (SD, 0.6) each month before v 0.4 (0.7) after treatment; p < 0.001) and aura duration (mean, 27 (SD, 11) minutes before v 8 (14) after treatment; p < 0.001). Furthermore, more than three quarters of those patients with a reduction of aura symptoms experienced a significant reduction of frequency of migraine attacks (mean, 2.1 (SD, 1.0) each month before v 1.2 (1.1) after treatment; p < 0.001). Lamotrigine was highly effective in reducing migraine aura and migraine attacks. The strong correlation between reduction of aura symptoms and migraine attacks stresses the potential role of aura-like events and possibly cortical spreading depression as a trigger for trigeminal vascular activation, and subsequently the development of migraine headaches.
Weitere Infos finden sich hier.
